Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Autoimmune Liver Disease
In what clinical scenario do you initiate the use of ileal bile acid transport (IBAT) inhibitors in the management of cholestatic liver disease?
Related Questions
In what clinical scenario would you consider the use of budesonide over prednisone as part of the pharmacologic management of autoimmune hepatitis?
What patient factors guide your selection of maintenance therapies for a patient with auto-immune hepatitis?
How do you prefer to manage IgG-4 related hepato-biliary disease, especially if there are similarities in imaging findings to other immune mediated liver diseases?
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
What is your approach to induction therapy and maintenance therapy for patients with autoimmune hepatitis?
How do you manage liver enzyme elevations in patients with PBC after starting elanifibranor?
In a serologic evaluation for immune-mediated liver disease, what further workup do you pursue when low immunoglobulins are identified?
What is your approach to the management of anti-pruritic therapies in patients with cholestatic liver disease?
How do you balance infection risk in patients with immune-mediated liver disease on chronic immunosuppression (ex: prednisone, AZA, MMF, etc)?
What is your approach to treatment of immune-mediated overlap syndromes, such as AIH-PBC?
